GoAI
Get started
Belite Bio, Inc logo

Belite Bio, Inc

BLTE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$161.06

−$0.88 · -0.54%

Aug 21, 4:00 PM ET

BLTE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

49

Neutral

Sentiment

57

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $161.06

52-week range

Current $161.06

Open
$164.02
Previous close
$161.94
Volume
111.22K
Market cap
6.46B USD
50-day average
$154.64
+4.15% above average
200-day average
$155.41
+3.64% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.01B USD
EV / EBITDA
-64.97×
Earnings yield
-1.45%
Free cash flow yield
-0.69%

Profitability & efficiency

Return on equity
-10.07%
Return on assets
-9.94%
Return on invested capital
-10.92%

Financial health

Current ratio
50.02×

Financial statements

Income trends

Operating income

−84.21M USD-110.54%

Net income

−77.61M USD-114.73%
Income trends across reported periods−2.21M USD−32.03M USD−61.85M USD−91.66M USDOperating income, FY2021: −9.8M USDOperating income, FY2022: −12.82M USDOperating income, FY2023: −31.67M USDOperating income, FY2024: −40M USDOperating income, FY2025: −84.21M USDNet income, FY2021: −9.67M USDNet income, FY2022: −12.65M USDNet income, FY2023: −31.63M USDNet income, FY2024: −36.14M USDNet income, FY2025: −77.61M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −9.8M USD. Operating income FY2022 −12.82M USD. Operating income FY2023 −31.67M USD. Operating income FY2024 −40M USD. Operating income FY2025 −84.21M USD. Net income FY2021 −9.67M USD. Net income FY2022 −12.65M USD. Net income FY2023 −31.63M USD. Net income FY2024 −36.14M USD. Net income FY2025 −77.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development45.38M USD29.94M USD24.84M USD8.87M USD7.42M USD
Selling, general, and administrative38.83M USD10.06M USD6.82M USD3.95M USD2.38M USD
Operating expenses84.21M USD40M USD31.67M USD12.82M USD9.8M USD
Interest income—3.74M USD74K USD23K USD5K USD
Interest expense—20K USD25K USD16K USD—
Depreciation and amortization464K USD449K USD399K USD198K USD30K USD
Operating income−84.21M USD−40M USD−31.67M USD−12.82M USD−9.8M USD
Net income−77.61M USD−36.14M USD−31.63M USD−12.65M USD−9.67M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+6.00%
11 comparable reports
Latest EPS result
-0.7
Estimate -0.73 · Beat by 4.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.26-0.45-0.65-0.84Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual -0.32, estimate -0.3, surprise -6.67%, Miss. Q2 2025, reported May 13, 2025: actual -0.45, estimate -0.36, surprise -25.00%, Miss. Q3 2025, reported Aug 11, 2025: actual -0.5, estimate -0.47, surprise -6.38%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.65, estimate -0.53, surprise -22.64%, Miss. Q1 2026, reported Mar 2, 2026: actual -0.38, estimate -0.56, surprise +32.14%, Beat. Q2 2026, reported May 20, 2026: actual -0.34, estimate -0.6, surprise +43.33%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.7, estimate -0.73, surprise +4.11%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.798, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$224

39.08% upside
Past 12 months12-month forecastHigh $270Average $224Low $206

BLTE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BLTE

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Emerging Markets ETF logoState Street SPDR Portfolio Emerging Markets ETFSPEM
Market value
2.02M
Weight
0.01%
AUM
17.57B USD
Expense ratio
0.07%
Price / 1D
$52.38+0.61%
ActivePassive International Equity ETF logoActivePassive International Equity ETFAPIE
Market value
668.72K
Weight
0.06%
AUM
953.79M USD
Expense ratio
0.45%
Price / 1D
$39.766+1.16%
Fidelity Nasdaq Composite Index ETF logoFidelity Nasdaq Composite Index ETFONEQ
Market value
606.95K
Weight
0.01%
AUM
10.35B USD
Expense ratio
0.21%
Price / 1D
$103.14+0.41%
State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
511.89K
Weight
0.11%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
364.37K
Weight
0.71%
AUM
51.06M USD
Expense ratio
0.65%
Price / 1D
$54.415+1.01%
Even Herd Long Short ETF logoEven Herd Long Short ETFEHLS
Market value
210.04K
Weight
0.36%
AUM
59.5M USD
Expense ratio
2.62%
Price / 1D
$25.525+0.10%
T. Rowe Price Innovation Leaders ETF logoT. Rowe Price Innovation Leaders ETFTNXT
Market value
11.98K
Weight
0.07%
AUM
18.54M USD
Expense ratio
0.49%
Price / 1D
$28.5422-0.48%

Continue in GoAI

Research BLTE

research.disclaimer